Boqii Holding Limited — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2024, with comparisons to fiscal 2023 and 2022. This is an annual report, not a standalone 2023 Q4 filing; separate quarterly Q4 results are not provided here. Financial figures below are in RMB unless otherwise noted.
Business context and financial performance
Boqii operates a China-focused pet-products and services platform through online sales, third-party e-commerce stores, offline distribution, marketing services and a pet-owner community. The Cayman Islands parent has no material operations of its own; much of the China business is conducted through VIEs consolidated under contractual arrangements.
| Metric | FY2024 | FY2023 | Change / context |
|---|---|---|---|
| Net revenue | RMB709.4 million (US$98.2 million) | RMB1,092.1 million | Down 35.0% |
| Product sales | RMB680.1 million | RMB1,048.5 million | Down 35.1%; about 95.9% of revenue |
| Marketing and other services revenue | RMB29.2 million | RMB43.6 million | Down 33.0% |
| Gross profit / gross margin | RMB140.7 million / 19.8% | RMB233.5 million / 21.4% | Gross profit down 39.7%; margin down 1.6 percentage points |
| Operating loss | RMB60.2 million | RMB103.8 million | Loss narrowed 42.0% |
| Net loss | RMB68.9 million (US$9.5 million) | RMB106.0 million | Loss narrowed 35.0%; losses continued |
| Operating cash flow | RMB(25.4) million | RMB(54.1) million | Cash use decreased, but remained negative |
| Cash and cash equivalents | RMB72.7 million (US$10.1 million) | RMB89.9 million | Down from prior year; short-term investments were nil at year-end |
| Working capital | RMB206.2 million (US$28.6 million) | RMB210.0 million | Positive, but slightly lower |
| Borrowings and other debt | RMB15.2 million short-term borrowings; RMB43.9 million non-current other debt | RMB86.3 million short-term borrowings; RMB102.8 million non-current other debt | Debt balances declined; short-term borrowings outstanding at year-end were subsequently repaid |
Gross margin on product sales fell to 17.6% from 19.6%. The company attributed the overall margin decline primarily to lower service revenue, which carries higher margins. FY2024 GMV was RMB1,591.8 million, down from RMB2,564.0 million; private-label products represented 24.9% of GMV versus 17.3% in FY2023, despite lower private-label GMV in absolute terms.
Material changes and management outlook
- Management said the revenue decline reflected a strategy focused more on profitability than sales volume. Operating expenses fell 31.3%, including lower fulfillment and sales-and-marketing costs; general and administrative expenses rose 27.3%, partly due to financing-related professional fees and share-based compensation.
- Offline distribution grew to 25.1% of revenue from 17.4%, while third-party e-commerce platform revenue declined. Management aims to expand private labels, offline relationships and cost-effective customer acquisition. No quantified revenue, earnings or margin guidance is provided.
- Management stated that available cash, cash equivalents, short-term investments and borrowing capacity should cover anticipated needs for at least 12 months. This outlook is subject to working-capital needs, financing access and the company’s continued operating cash outflows.
- During FY2024, the company reported gross proceeds of approximately US$3.3 million from ADS sales under a purchase agreement and US$3.5 million from a private placement. These equity financings increased share count and may dilute shareholders.
Risks, contingencies and unusual items
- Auditor and payment concerns: On July 26, 2024, the company dismissed PwC and appointed Assentsure. PwC raised concerns about the substance of approximately US$6 million of payments: a US$4.1 million M&A-advisor deposit, an RMB3 million interest-free loan to an individual and related transfers, and US$1.5 million paid to a financial advisor for financing work. PwC said further audit work and investigation could have materially affected confidence in the financial statements; PwC did not expand its audit before dismissal. The filing says the US$4.1 million deposit was fully returned and the RMB3 million loan was fully collected by the filing date. Assentsure issued an unqualified opinion on the FY2024 financial statements. Investors should not treat that opinion as resolving the specific concerns PwC identified.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective as of March 31, 2024. The filing describes weaknesses involving qualified U.S. GAAP/SEC reporting staff, documented period-end procedures (including logistics and vendor rebates), and loan approvals. Remediation was underway; the company had not concluded the weaknesses were fully remedied.
- VIE and China regulatory exposure: VIEs generated 71.2% of FY2024 revenue. Investors own shares in the Cayman holding company, not equity in the VIEs. Contractual control arrangements have not been tested in a PRC court, and changes in regulation or enforcement could impair control or consolidation.
- Liquidity and operating risks: The company has a history of losses and negative operating cash flow, declining sales, dependence on third-party platforms and concentrated supplier exposure. Royal Canin China represented 26% of purchases in FY2024. The filing also identifies risks from customer demand, competition, product quality, foreign-exchange controls and the ability to transfer cash from China.
- Regulatory and other items: The company disclosed prior fines of RMB100,000 in 2021 for illegal information on its app and RMB5,000 in 2023 relating to unsubscribe requests; it says both matters were rectified. Leases had not been registered with relevant PRC authorities, potentially exposing the company to fines. The filing reports no material pending litigation and no dividends planned in the near future.
Important facts for investors to verify
- Review the auditor-change disclosure and PwC’s filed letter; seek updates on the investigation and the US$6 million of questioned payments, including supporting documentation and any subsequent findings.
- Track whether the identified internal-control weaknesses are remediated and whether future filings report effective controls.
- Assess the sustainability of the sharp revenue and GMV declines, gross-margin recovery, and the shift toward private-label and offline sales.
- Verify cash availability and debt repayments after year-end, ongoing operating cash needs, and any new financing or dilution.
- Evaluate VIE enforceability, PRC regulatory and cash-transfer exposure, and the company’s dependence on key platforms and suppliers.